New endometriosis and diabetes treatments earn PBAC approval
The committee also recommended romosozumab (Evenity) be subsidised for severe osteoporosis in first-line settings.
A new endometriosis treatment has been given the PBS green light just three months after it was approved by the TGA.
The once-daily combination pill Ryeqo, which contains the gonadotropin-releasing hormone antagonist relugolix 40mg, oestradiol 1mg and norethisterone 0.5mg, was initially indicated for uterine fibroids.
